GlassScriptPhysician profile
Samayra Miranda Rodriguez
NPI 1427289594
$3,687.22
in general payments reported to CMS, 2019-2025
13 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $1,305 · 2021: $326 · 2022: $297 · 2023: $450 · 2024: $350 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,162.73 | 2019-2022 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $592.73 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $470.97 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $401.76 | 2019-2024 | Lokelma |
| Sanofi-Aventis U.S. LLC | $330.73 | 2019-2023 | |
| Bayer Puerto Rico INC. | $306.25 | 2023-2025 | Kerendia |
| E.R. Squibb & Sons, L.L.C. | $100.00 | 2019 | |
| Medtronic, INC. | $90.00 | 2023 | Minimed 780g |
| Abbott Laboratories | $81.32 | 2019-2022 | |
| Dexcom, INC. | $80.25 | 2024 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $30.00 | 2024 | Xarelto |
| Amgen INC. | $22.29 | 2023 | Repatha, Prolia, Evenity |
| Vifor Pharma, INC. | $18.19 | 2025 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samayra Miranda Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.